HoyleCohen’s Armata Pharmaceuticals ARMP Stock Holding History

HoyleCohen’s Portfolio ARMP Stock Details ARMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,357	Closed	-$6K	–	184
2019 Q1	$6K	Buy	1,357 +571	+73%	+$2.17K	﹤0.01%	178
2018 Q4	$2K	Hold	786	–	–	﹤0.01%	164
2018 Q3	$11K	Hold	786	–	–	﹤0.01%	165
2018 Q2	$12K	Hold	786	–	–	﹤0.01%	159
2018 Q1	$12K	Hold	786	–	–	﹤0.01%	153
2017 Q4	$11K	Buy	+786	New	+$11.6K	﹤0.01%	153

Other funds holding ARMP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HoyleCohen's ARMP Position: Q2 2019 in Review

HoyleCohen sold out of Armata Pharmaceuticals (ARMP) in Q2 2019, closing a stake of 1,357 shares — an estimated $6K sold.

HoyleCohen first reported a position in ARMP in Q4 2017 and held it in 6 quarters. The position peaked at $12K in Q2 2018. 12 funds tracked by Wall St. Rank hold ARMP as of Q2 2019.

HoyleCohen reported no remaining Armata Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
HoyleCohen sold 1,357 Armata Pharmaceuticals shares in Q2 2019, an estimated $6K.
HoyleCohen first reported a position in Armata Pharmaceuticals in Q4 2017 and held it in 6 quarters.
HoyleCohen's Armata Pharmaceuticals position peaked at $12K in Q2 2018.
12 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2019.

Based on HoyleCohen's 13F filing for Q2 2019, filed 9 Aug 2019.